Munich (pta009/24.07.2017/08:05) - NOT FOR PUBLICATION OR DISTRIBUTION WITHIN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA
* Co-investment planned for drug development cooperation with Santo Holding
* Participation of up to 30% in development costs and future revenue from marketing of FYB202
* Funding secured through private placement Transaction
Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY), a leading independent developer of biosimilar drugs, today announced the signing of a term sheet for the joint development of FYB202 under a co-investment arrangement with Santo Holding (Deutschland) GmbH. Under the terms of the agreement, Formycon is to make an in-kind contribution of its FYB202 project, with Formycon participating in up to 30% of total costs and revenue and Santo holding the remaining interest of at least 70%. The objective will be to drive forward with the development of FYB202 through to regulatory approval. Once the pilot phase has been successfully completed, development costs, including project investments to date, will be borne by the two partners in proportion to their ownership stakes. From the standpoint of Formycon, its participation of up to 30% in worldwide marketing proceeds from FYB202 represents a significant step forward in its strategic development and marks a key advance on its path to becoming an integrated pharmaceutical company.
In addition, the company today announced the closing of a private placement transaction, generating gross issuance proceeds of EUR 6.00 million. Under the transaction, Formycon placed 190,500 shares newly issued from its approved capital to selected institutional investors at a price of EUR 31.50 per share, thereby raising its legal registered capital (Grundkapital) likewise by EUR 190,500.00, from EUR 9,099,603.00 to EUR 9,290,103.00. The new shares will be approved for trading on the Frankfurt Stock Exchange following completion of issuance.
Proceeds from the transaction will be used to fund the planned co-investment as well as ongoing development of the company's biosimilar drug portfolio, so that its already established market position may be further strengthened. Formycon currently holds, with the inclusion of short-term receivables, cash and cash equivalents of approx. EUR 22 million. Formycon was advised on the capital-raising transaction by First Berlin Securities Brokerage GmbH.
This press release may contain forward-looking statements and information which are based on our current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, performance of the company, development of the products and the estimates given here.
Such known and unknown risks and uncertainties comprise, among others, the research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety, patent litigation, contractual risks and dependencies from third parties. With respect to pipeline products, Formycon AG does not provide any representation, warranties or any other guarantees that the products will receive the necessary regulatory approvals or that they will prove to be commercially exploitable and/or successful.
Formycon AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated.
This document neither constitutes an offer to sell nor a solicitation of an offer to buy or subscribe for securities of Formycon AG. No public offering of securities of Formycon AG will be made nor is a public offering intended.
This document and the information contained therein may not be distributed in or into the United States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would be prohibited. This document does not constitute an offer for the sale of securities in the United States.